Fundraising FoxLuma Group — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases.
AI & Machine LearningBiotechDigital HealthJersey City, US
Cheng Zhang(CEO, Co-Founder)inMarcel van der Brug(Scientific Advisor, Co-Founder)inNick Johnson(Technology Advisor, Co-Founder)inDaniel Elgort(Chief Data and Analytics Officer)inLaura Carter(Chief Scientific Officer)inRobert Kim(Chief Medical Officer)in
Co-investorsaMoonSanofi VenturesInnovation EndeavorsCantos VenturesCatalio Capital Management, LPDuke Capital Partners+5 more
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Co-investorsCoastCapCTI Life Sciences Fund L.P.Felix JahnFJ LabsSofinnova VenturesvenBio Partners+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.